Factors driving the aspirin exacerbated respiratory disease phenotype

American Journal of Rhinology and Allergy

Volumn 29, Issue 1, 2015, Pages 35-40

  Steinke, John W ^a,b   Borish, Larry ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 4; LEUKOTRIENE C4 SYNTHASE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; STAT6 PROTEIN; CYSTEINE; CYSTEINYL-LEUKOTRIENE; LEUKOTRIENE; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; PROSTAGLANDIN E RECEPTOR;

ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; CYTOKINE PRODUCTION; DESENSITIZATION; EOSINOPHIL; HUMAN; HYPEREOSINOPHILIA; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; MAST CELL; MEDIATOR RELEASE; PROTEIN EXPRESSION; UPREGULATION; CHEMICALLY INDUCED; DRUG EFFECTS; EOSINOPHILIA; IMMUNOLOGY; PHENOTYPE; PHYSIOLOGY; RESPIRATORY TRACT DISEASE;

ASPIRIN; CYSTEINE; EOSINOPHILIA; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LEUKOTRIENE E4; LEUKOTRIENES; MAST CELLS; PHENOTYPE; RECEPTORS, LEUKOTRIENE; RECEPTORS, PROSTAGLANDIN E; RESPIRATORY TRACT DISEASES;

EID: 84921046769     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2015.29.4123     Document Type: Article

References (76)

1. Samter M, and Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68: 975-983, 1968.
2. Szczeklik A, and Stevenson DD. Aspirin-induced asthma: Advances in pathogenesis and management. J Allergy Clin Immunol 104: 5-13, 1999.
3. Szczeklik A, and Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 55: S42-SS44, 2000.
4. Berges-Gimeno MP, Simon RA, and Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89: 474-478, 2002.
5. Vally H, Taylor ML, and Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 57: 569-574, 2002.
6. Payne SC, Early SB, Huyett P, et al. Evidence for distinct histologic profile of nasal polyps with and without eosinophilia. Laryngoscope 121: 2262-2267, 2011.
7. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 94: 652-657, 2005.
8. Szczeklik A, and Sanak M. Molecular mechanisms in aspirin-induced asthma. ACI International 12/ 4: 171-176, 2000.
9. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116: 970-975, 2005.
10. Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 166: 301-306, 2002.
11. Daffern PJ, Muilenburg D, Hugli TE, and Stevenson DD. Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 104: 559-564, 1999.
12. Perez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotiene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005; 115: 1189-1196, 2005.
13. Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 160: 291-296, 1999.
14. Ying S, Meng Q, Scadding G, et al. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 117: 312-318, 2006.
15. Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: Importance to eosinophilia and asthma. J Allergy Clin Immunol 111: 342-349, 2003.
16. Beller TC, Friend DS, Maekawa A, et al. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci USA 101: 3047-3052, 2004.
17. Steinke JW. Editorial: Yin-Yang of EP receptor expression. J Leuk Biol 92: 1129-1131, 2012.
18. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirinsensitive asthmatic subjects. Am Rev Respir Dis 143: 1025-1029, 1991.
19. Cardet JC, White AA, Barrett NA, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol. In practice 2: 208-213, 2014.
20. Payne SC. Re: Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract 2: 644, 2014.
21. Sampson AP, Cowburn AS, and Sladek K. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Archives Allergy Immunol 113: 355-357, 1997.
22. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101: 834-846, 1998.
23. Arm JP, O'Hickey SP, Spur BW, and Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 140: 148-153, 1989.
24. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347: 1493-1499, 2002.
25. Lee TH, Austen KF, Corey EJ, and Drazen JM. Leukotriene E4- induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci USA 81: 4922-4925, 1984.
26. Christie PE, Schmitz-Schumann M, Spur BW, and Lee TH. Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur Respir J 6: 1468-1473, 1993.
27. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341: 989-990, 1993.
28. Nonaka Y, Hiramoto T, and Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337: 281-288, 2005.
29. Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206: 2543-2555, 2009.
30. Kanaoka Y, Maekawa A, and Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 288: 10967-10972, 2013.
31. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793, 1999.
32. Christie PE, Smith CM, and Lee TH. The potent and selective sulfidopeptide leukotriene antagonists, SK&F 104353, inhibits aspirininduced asthma. Am Rev Resir Dis 144: 957-958, 1991.
33. Dahlén B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 161: S137-S141, 2000.
34. Walch L, Norel X, BäckM, et al. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol 137: 1339-1345, 2002.
35. White A, Bigby T, and Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97: 190-195, 2006.
36. Schmid M, Göde U, Schäfer D, and Wigand ME. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol 119: 277-280, 1999.
37. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin- induced bronchoconstriction and urinary LTE4 excretion in aspirin- sensitive asthma. Am J Respir Crit Care Med 153: 572-575, 1996.
38. Feng C, Beller EM, Bagga S, and Boyce JA. Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses. Blood 107: 3243-3250, 2006.
39. Murakami M, Nakashima K, Kamei D, et al. Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2. J Biol Chem 278: 37937-37947, 2003.
40. Gosepath J, Brieger J, and Mann WJ. New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis. Am J Rhinol 19: 111-116, 2005.
41. Steinke JW, Culp JA, Kropf E, and Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 124: 724-730 e4, 2009.
42. Bachert C, Wagenmann M, Hauser U, and Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 99: 837-842, 1997.
43. Bachert C, Gevaert P, and van Cauwenberge P. Nasal polyposis- A new concept on the formation of polyps. ACI International 11: 130-135, 1999.
44. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. Amer J Resp Cell Mol Biol 17: 683-690, 1997.
45. Hamilos DL, Leung DY, Huston DP, et al. GM-CSF, IL-5, and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 28: 1145-1152, 1998.
46. Kamil A, Ghaffar O, Lavigne F, et al. Comparison of inflammatory cell profile and Th2 cytokine expression in the ethmoid sinuses, maxillary sinuses, and turbinates of atopic subjects with chronic sinusitis. Otolaryngol Head Neck Surg 18: 804-809, 1998.
47. Riechelmann H, Deutschle T, Rozsasi A, et al. Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin Exp Allergy 35: 1186-1191, 2005.
48. Van Bruaene N, Perez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 121: 1435- 1441.e1-e3, 2008.
49. Hamilos DL, Leung DY, Wood R, et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 96: 537-544, 1995.
50. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61: 1280-1289, 2006.
51. Shome GP, Tarbox J, Shearer M, and Kennedy R. Cytokine expression in peripheral blood lymphocytes before and after aspirin desensitization in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 28: 706-710, 2007.
52. Steinke JW, Liu L, Huyett P, et al. Prominent role of interferon- in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 132: 856-865.e3, 2013.
53. Kanda A, Driss V, Hornez N, et al. Eosinophil-derived IFN- induces airway hyperresponsiveness and lung inflammation in the absence of lymphocytes. J Allergy Clin Immunol 124: 573-582, 2009.
54. Akuthota P, Xenakis JJ, and Weller PF. Eosinophils: Offenders or general bystanders in allergic airway disease and pulmonary immunity? J Innate Immun 3: 113-119, 2011.
55. Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol 85: 117-123, 2009.
56. Spencer LA, Melo RC, Perez SA, et al. Cytokine receptor-mediated trafficking of preformed IL-4 in eosinophils identifies an innate immune mechanism of cytokine secretion. Proc Natl Acad Sci USA 103: 3333-3338, 2006.
57. Milanovic M, Terszowski G, Struck D, et al. IFN consensus sequence binding protein (Icsbp) is critical for eosinophil development. J Immunol 181: 5045-5053, 2008.
58. de Bruin AM, Buitenhuis M, van der Sluijs KF, et al. Eosinophil differentiation in the bone marrow is inhibited by T cell-derived IFN-. Blood 116: 2559-2569, 2010.
59. Hsieh FH, Lam BK, Penrose JF, et al. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: Profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med 193: 123-133, 2001.
60. Mellor EA, Austen KF, and Boyce JA. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med 195: 583-592, 2002.
61. Mellor EA, Frank N, Soler D, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci USA 100: 11589-11593, 2003.
62. Thivierge M, StankováJ, and Rola-Pleszczynski M. IL-13 and IL-4 up-regulate cysteinyl leukotriene 1 receptor expression in human monocytes and macrophages. J Immunol 167: 2855-2860, 2001.
63. Early SB, Barekzi E, Negri J, et al. Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN- on peripheral immune cells. Am J Respir Cell Mol Biol 36: 715-720, 2007.
64. Yano T, Hopkins HA, Hempel SL, et al. Interleukin-4 inhibits lipopolysaccharide- induced expression of prostaglandin H synthase-2 in human alveolar macrophages. J Cell Physiol 165: 77-82, 1995.
65. Dworski R, and Sheller JR. Differential sensitivities of human blood monocytes and alveolar macrophages to the inhibition of prostaglandin endoperoxide synthase-2 by interleukin-4. Prostaglandins 53: 237-251, 1997.
66. Steinke JW, Negri J, Liu L, et al. Aspirin activation of eosinophils and mast cells: Implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193: 41-47, 2014.
67. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 161: 391-398, 2000.
68. Liu T, Laidlaw TM, Katz HR, and Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci USA 110: 16987-16992, 2013.
69. Kim YK, Uno M, Hamilos DL, et al. Immunolocalization of CD34 in nasal polyposis. Effect of topical corticosteroids. Am J Respir Cell Mol Biol 20: 388-397, 1999.
70. Denburg JA. Haemopoietic mechanisms in nasal polyposis and asthma. Thorax 55: S24-S25, 2000.
71. Sweet JM, Stevenson DD, Simon RA, and Mathison DA. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis- asthma. J Allergy Clin Immunol 85: 59-65, 1990.
72. Stevenson DD, and Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 118: 801-804, 2006.
73. Juergens UR, Christiansen SC, Stevenson DD, and Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 96: 148-156, 1995.
74. Woszczek G, Pawliczak R, Qi HY, et al. Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J Immunol 175: 5152-5159, 2005.
75. Perez-G M, Melo M, Keegan AD, and Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 168: 1428-1434, 2002.
76. Tegeder I, Pfeilschifter J, and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072, 2001.